| |
| |
|
| Insider
Information: |
Sigal Charles Elliott |
| Relationship: |
Director |
| City: |
Princeton |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
68,744 |
|
|
Indirect Shares
|
326,100 |
|
|
| Direct
Value |
$56,908 |
|
|
|
Indirect Value
|
$624,278 |
|
|
| Total
Shares |
394,844 |
|
|
| Total
Value |
$681,186 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Adaptimmune Therapeutics PLC |
ADAP |
Director |
2016-05-19 |
52,938 |
2016-05-19 |
314,100 |
Premium* |
|
|
Surface Oncology, Inc. |
SURF |
Director |
2018-04-23 |
0 |
2023-09-08 |
0 |
Premium* |
|
|
Vir Biotechnology, Inc. |
VIR |
Director |
2023-05-22 |
15,806 |
2023-05-22 |
10,000 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
|
0 |
2022-08-22 |
2,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
16 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SURF |
Surface Oncology, Inc. |
Director |
– • – |
2023-09-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(45,453) |
0 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,027 |
15,806 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-03-01 |
4 |
AB |
$22.73 |
$56,816 |
I/I |
2,500 |
10,000 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-01-05 |
4 |
AB |
$24.96 |
$62,396 |
I/I |
2,500 |
7,500 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-01-04 |
4 |
AB |
$25.25 |
$63,136 |
I/I |
2,500 |
5,000 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-01-03 |
4 |
AB |
$25.60 |
$63,993 |
I/I |
2,500 |
2,500 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2022-08-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,000 |
|
% |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2022-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,405 |
9,779 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2021-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
3,374 |
3,374 |
0 |
- |
|
| SURF |
Surface Oncology, Inc. |
Director |
– • – |
2018-04-23 |
4 |
A |
$0.00 |
$0 |
I/I |
45,453 |
45,453 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2016-05-19 |
4 |
B |
$1.56 |
$23,400 |
I/I |
15,000 |
314,100 |
2.1 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2016-05-18 |
4 |
B |
$1.55 |
$23,250 |
I/I |
15,000 |
299,100 |
2.1 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2016-05-17 |
4 |
B |
$1.53 |
$22,950 |
I/I |
15,000 |
284,100 |
2.1 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2016-05-16 |
4 |
B |
$1.50 |
$22,500 |
I/I |
15,000 |
269,100 |
2.1 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
52,938 |
|
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2016-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
254,100 |
|
- |
|
16 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
